openPR Logo
Press release

Global Breast Cancer Vaccine Treatment Offers Billion Dollars Opportunity For Vaccine Developers

07-08-2017 01:51 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Breast Cancer Vaccine Treatment Offers Billion Dollars

“Global Breast Cancer Vaccine Market and Clinical Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global breast cancer vaccine development market. Currently there is no single breast cancer vaccine commercially available in the market. This report analyzes the ongoing clinical trial of 36 breast cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the vaccine. Most of the breast cancer vaccines in clinical trials are in preclinical phase followed by Phase-I trials. The advance stage of development of breast cancer vaccine in clinical trials across the globe is in Phase-III.

For Report Sample Contact: or +91-11-47067990

Download Report:

Report Table of Contents

What are Cancer Vaccines?

Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

Mechanism of Breast Cancer Vaccine
3.1 Principle Strategies for Eliciting Immune System
3.1.1 Overcoming Immune Suppression
3.1.2 Modulation of Immune Checkpoints
3.2 Immunogenicity and Responses to Therapies
3.3 Breast Cancer Therapeutic Vaccines

Global Breast Cancer Incidence
4.1 US
4.2 Europe
4.3 Asia
4.4 Rest of the World

Global Breast Cancer Vaccine Market Current Scenario
5.1 Unexplored Opportunity
5.2 Global Breast Cancer Vaccine Pipeline Overview

Need for Personalized Breast Cancer Vaccines

Global Breast Cancer Vaccine Market Dynamics
7.1 Favorable Parameters
7.2 Commercialization Challenges

Global Breast Cancer Vaccine Market Future Prospects

FDA Guideline for the Development and Marketing of Cancer Vaccines
9.1 Considerations for Both Early and Late Phase Clinical Trials
9.1.1 Patient Population
9.1.2 Monitoring The Immune Response
9.1.3 Biomarkers As Evidence Of Efficacy
9.1.4 Adjuvants Used To Stimulate Immune Response
9.1.5 Multi-Antigen Vaccines
9.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines
9.1.7 Concomitant And Subsequent Therapies
9.2 Considerations for Early Phase Clinical Trials
9.2.1 Starting Dose And Dosing Schedule
9.2.2 Booster And Maintenance Therapy
9.2.3 Dose Escalation
9.2.4 Single-Arm Versus Randomized Phase 2 Trials In Early Development
9.3 Considerations For Late Phase Clinical Trials
9.3.1 Safety Profile From Early Phase Clinical Trials
9.3.2 Endpoints
9.3.3 Statistical Issues
9.3.4 Control Issues
9.3.5 Delayed Vaccine Effect
9.3.6 Autologous Vaccine Trials
9.3.7 Accelerated Approval Regulations

Global Breast Cancer Vaccine Clinical Pipeline by Company and Phase
10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III

Discontinued and Suspended Breast Cancer Vaccine in Clinical Pipeline by Company and Phase
11.1 Suspended
11.2 No Development Reported
11.3 Discontinued

Competitive Landscape
12.1 Advaxis
12.2 AlphaVax
12.3 AVAX Technologies
12.4 Dendreon Corporation
12.5 Galena Biopharma
12.6 Generex Biotechnology
12.7 GlaxoSmithKline
12.8 Immune Design
12.9 Imugene
12.10 Immunovative Therapies
12.11 Immunovaccine
12.12 Inovio Pharmaceuticals
12.13 Merck
12.14 NewLink Genetics
12.15 Recombio
12.16 TapImmune
12.17 ViroMed

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Breast Cancer Vaccine Treatment Offers Billion Dollars Opportunity For Vaccine Developers here

News-ID: 615059 • Views: 888

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report:,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases

More Releases for Vaccine

Tetanus Toxoid Vaccine Market
The report for Global Tetanus Toxoid Vaccine Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. Market Highlights: Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone
Key Tools for Innovative Vaccine Designs: Vaccine Adjuvants
The report “NORTH AMERICA VACCINE ADJUVANTS MARKET” provides the detail description of market segmentation, applications, growth, size, and outlook. The market is projected to reach USD $278 Million by 2024, at a CAGR of 11.3%. An adjuvant is an immunological agent, which modifies the effect of other agents. Adjuvants can also act as an irritant, which engages and amplifies the body immune response. Adjuvants are added to vaccines to boost the
Vaccine Market Demand is Increasing
U.S. Vaccine Market: Snapshot The overall vaccine industry has strengthened itself in terms of its growth rate, with a relatively higher growth rate than most other healthcare market segments. Vaccination has been an invaluable addition to better public health, and has helped millions of children, adults and animals from deadly diseases. The CDC stated in a report that diseases such as diphtheria, polio, and smallpox have been fully eliminated, while measles,
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Peanut Allergy Vaccine Market
Allergies are medical conditions caused primarily by hypersensitivity of the immune system to some external stimulus. Allergy may cause anaphylaxis—a medical condition that can cause irritation of the skin, swelling of throat, shortness of breath, and in some cases, death. Allergies are caused by various allergens such as pollen grains, or certain foods such as peanuts. Vaccination is the process of administering antigenic material or a vaccine to stimulate one’s
Shingles Vaccine Market
The shingles vaccine market revenue is expected to grow at a robust rate over the forecast period. Shingles, also known as herpes zoster, is a viral infection that affects the cranial nerves that originate in the brain. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus can stay dormant for many years in the human body. Therefore, anyone who has had